New Evidence-based Research will be Unveiled During 'Ask the Experts’ at ONS Congress in April
Columbus, OH, April 04, 2007 --(PR.com)-- New evidence-based research for determining adherence to the NIOSH definition of a closed-system will be unveiled during ‘Ask the Experts’ at the ONS Congress on Wednesday, April 25 in Las Vegas, NV.
‘Ask the Experts’ will be held from 1pm-2pm on Wednesday, April 25 in the Carmel Pharma, Inc. booth #823. This is an exclusive opportunity to interact with clinical leaders in the safe handling arena, and preview new evidence-based research which substantiates that PhaSeal is the only transfer device that meets the definition of closed. The ‘Ask the Experts’ panel will be led by:
- James A. Jorgenson, RPh, MS, FASHP, Administrative Director for Pharmacy Services, University of Utah Health Care, Salt Lake City, Utah
Project advisor for this new research
Regarding the significance of this event and sharing this research, Jorgenson says, “As awareness of safe handling continues to increase, it is important for practitioners to fully understand what systems meet the definition of closed in terms of offering complete protection.”
University Health Care is the only academic health care system in the Intermountain West. As part of that system, University Hospitals & Clinics offer services in more than 120 specialties and is consistently ranked as one of the country’s best hospitals by U.S. News & World Report. The system provides care for Utahans and residents of five surrounding states in a referral area encompassing more than 10 percent of the continental United States. The hospitals and clinics log more than 900,000 outpatient visits and more than 23,000 inpatient admissions each year. Its academic partners at the University of Utah School of Medicine and Colleges of Nursing, Pharmacy, and Health are internationally regarded research and teaching institutions.
The PhaSeal System is the only clinically proven closed-system drug transfer device available today, offering over 10 peer-reviewed, independent studies. The System consists of an Expansion Chamber that captures aerosols and vapors while equalizing the pressure in the vial, a Double membrane that ensures dry connections, and a Needle-Safe Design that enables the retrieval of all the drug from the vial.
The PhaSeal System is manufactured by Carmel Pharma ab in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the U.S. since 2000 and has been implemented in over 500 cancer centers, oncology practices, specialty pharmacies in the United States, including M.D. Anderson in Houston, TX, Texas Children’s and UCSF. If you have questions regarding the PhaSeal System or Carmel Pharma, Inc., please contact Christine Crooks, Director of Marketing at 1-866-487-9250 ext.202, or email them at info@carmelpharmausa.com.
###
‘Ask the Experts’ will be held from 1pm-2pm on Wednesday, April 25 in the Carmel Pharma, Inc. booth #823. This is an exclusive opportunity to interact with clinical leaders in the safe handling arena, and preview new evidence-based research which substantiates that PhaSeal is the only transfer device that meets the definition of closed. The ‘Ask the Experts’ panel will be led by:
- James A. Jorgenson, RPh, MS, FASHP, Administrative Director for Pharmacy Services, University of Utah Health Care, Salt Lake City, Utah
Project advisor for this new research
Regarding the significance of this event and sharing this research, Jorgenson says, “As awareness of safe handling continues to increase, it is important for practitioners to fully understand what systems meet the definition of closed in terms of offering complete protection.”
University Health Care is the only academic health care system in the Intermountain West. As part of that system, University Hospitals & Clinics offer services in more than 120 specialties and is consistently ranked as one of the country’s best hospitals by U.S. News & World Report. The system provides care for Utahans and residents of five surrounding states in a referral area encompassing more than 10 percent of the continental United States. The hospitals and clinics log more than 900,000 outpatient visits and more than 23,000 inpatient admissions each year. Its academic partners at the University of Utah School of Medicine and Colleges of Nursing, Pharmacy, and Health are internationally regarded research and teaching institutions.
The PhaSeal System is the only clinically proven closed-system drug transfer device available today, offering over 10 peer-reviewed, independent studies. The System consists of an Expansion Chamber that captures aerosols and vapors while equalizing the pressure in the vial, a Double membrane that ensures dry connections, and a Needle-Safe Design that enables the retrieval of all the drug from the vial.
The PhaSeal System is manufactured by Carmel Pharma ab in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the U.S. since 2000 and has been implemented in over 500 cancer centers, oncology practices, specialty pharmacies in the United States, including M.D. Anderson in Houston, TX, Texas Children’s and UCSF. If you have questions regarding the PhaSeal System or Carmel Pharma, Inc., please contact Christine Crooks, Director of Marketing at 1-866-487-9250 ext.202, or email them at info@carmelpharmausa.com.
###
Contact
Christine Crooks
866-487-9250
www.carmelpharma.com
866-487-9250
www.carmelpharma.com
Contact
Categories